Envestnet Asset Management Inc. Buys 167,641 Shares of Pfizer Inc. $PFE

Key Points

• Envestnet Asset Management increased its Pfizer stake by 1.8%, purchasing 167,641 additional shares and bringing its holdings to 9.51 million shares worth approximately $229.1 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77, exceeding the $0.68 consensus estimate, while revenue rose 2.6% year over year to $15.03 billion. The company maintained fiscal 2026 EPS guidance of $2.80–$3.00.
• Analysts have a consensus “Hold” rating with a $28.39 price target; shares recently traded at $28.41. Investors continue to weigh Pfizer’s pipeline, cost reductions and vaccine opportunities against declining COVID-related revenue, patent pressures and dividend-payout concerns.

Envestnet Asset Management Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,513,242 shares of the biopharmaceutical company's stock after acquiring an additional 167,641 shares during the period. Envestnet Asset Management Inc. owned approximately 0.17% of Pfizer worth $229,078,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Angeles Wealth Management LLC raised its holdings in shares of Pfizer by 2.2% in the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock valued at $410,000 after buying an additional 358 shares during the period. Manchester Financial Inc. grew its position in Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock valued at $317,000 after acquiring an additional 365 shares in the last quarter. Vermillion Wealth Management Inc. increased its stake in Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 382 shares during the period. Eagle Capital Management LLC lifted its position in shares of Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. Finally, Delta Financial Advisors LLC lifted its position in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock worth $709,000 after purchasing an additional 398 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Updated COVID-19 vaccine could support seasonal revenue. The FDA approved Pfizer and BioNTech’s 2026–2027 COMIRNATY XFG formula, targeting the XFG variant for older adults and certain younger high-risk individuals. The approval provides another opportunity to generate post-pandemic vaccine sales, although demand remains substantially below pandemic-era levels. Could a New Vaccine Formula XFG Give Pfizer and BioNTech a Post-Pandemic Revenue Boost?
• Positive Sentiment: RSV expansion remains a potential growth driver. Pfizer completed a Phase 3 study in Japan evaluating its RSVpreF vaccine in adults. While efficacy and regulatory outcomes are still pending, success could broaden the vaccine’s international and adult-market opportunity. Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential
• Positive Sentiment: Pipeline development and cost reductions support the longer-term case. Recent analysis highlights Pfizer’s newer medicines, business-development activity and cost-cutting program as possible offsets to declining COVID products and upcoming patent pressures. Pfizer: Poised For Gains With a New Drug Pipeline and Cost-Cutting Plans
• Neutral Sentiment: Analysts remain divided relative to AbbVie and Eli Lilly. Comparisons emphasize Pfizer’s restructuring, pipeline prospects, acquisitions and patent exposure, but do not identify a new company-specific earnings catalyst. Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
• Negative Sentiment: COVID revenue declines and valuation concerns remain overhangs. Commentary notes that Pfizer’s COVID products continue to shrink and overall revenue has been broadly flat, while another analysis argues the stock may already reflect benefits from an overseas pricing agreement. Pfizer Stock May Be Overvalued After Overseas Pricing Deal
• Negative Sentiment: High dividend yield raises payout-risk questions. Articles identify Pfizer as a high-yield stock with positive free cash flow but an unfavorable payout ratio, increasing investor sensitivity to earnings weakness and patent cliffs. Pfizer, Kraft, and UPS: Which Dividend Stock Is Safest?

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PFE. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Finally, BMO Capital Markets cut their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.39.

Pfizer Stock Up 0.8%

Shares of NYSE:PFE opened at $28.41 on Friday. The firm's 50 day moving average price is $26.98 and its 200 day moving average price is $26.41. The stock has a market cap of $161.91 billion, a price-to-earnings ratio of 37.38, a price-to-earnings-growth ratio of 1.88 and a beta of 0.34. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $29.21. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm's revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.